Advertisement

Renal Cancer pp 133-157 | Cite as

Natural History, Role of Biopsy, and Active Surveillance of Renal Masses

  • Benjamin T. Ristau
  • Anthony Corcoran
  • Marc C. Smaldone
  • Robert G. Uzzo
  • David Y. T. ChenEmail author
Chapter

Abstract

With increased utilization of cross-sectional imaging over the past few decades, we have observed a rise in asymptomatic, clinically localized, small renal masses (SRMs). Despite increased detection and treatment, mortality rates from kidney cancer remain relatively unchanged. This suggests that a proportion of small renal masses are indolent tumors that may not require surgical intervention. From these observations, active surveillance (AS) has emerged as an alternative management strategy in appropriately selected patients. Furthermore, the use of AS has provided the basis for describing the natural history of renal masses managed without intervention. As data from prospective registries continue to mature, we have observed that many incidental renal masses demonstrate slow growth kinetics with a low rate of progression to metastatic disease. Therefore, the use of AS appears to be a safe initial management option in patients with SRMs.

Keywords

Renal cell carcinoma Natural history Percutaneous biopsy Active surveillance Growth kinetics 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. Jama. 1999;281(17):1628–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer. 2008;113(1):78–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol. 2008;179(6):2131–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Russo P, Uzzo RG, Lowrance, W, Asnis-Alibozek, A, LaFrance, N, Libertino, JA, Pryma, DA, Divgi, CR, editors. Incidence of Benign Versus Malignant Renal Tumors in Selected Studies. Genitourinary Cancers Symposium, Orlando Fl, USA; 2012.Google Scholar
  8. 8.
    Crispen PL, Boorjian SA, Lohse CM, Sebo TS, Cheville JC, Blute ML, et al. Outcomes following partial nephrectomy by tumor size. J Urol. 2008;180(5):1912–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Remzi M, Ozsoy M, Klingler HC, Susani M, Waldert M, Seitz C, et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol. 2006;176(3):896–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefPubMedGoogle Scholar
  11. 11.
    Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010;102(9):605–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4):1271–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28(2):311–7.Google Scholar
  14. 14.
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58(6):843–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. Jama. 1998;280(11):975–80.CrossRefPubMedGoogle Scholar
  16. 16.
    Dall’Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.CrossRefPubMedGoogle Scholar
  18. 18.
    Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. 2015;33(3):272–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology. 1995;197(3):589–97.CrossRefPubMedGoogle Scholar
  20. 20.
    Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int J Urol. 1995;2(2):71–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J Urol. 2004;172(3):863–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Oda T, Miyao N, Takahashi A, Yanase M, Masumori N, Itoh N, et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int J Urol. 2001;8(9):473–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S. Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer. 2007;110(5):1010–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J Urol. 2008;180(2):505–8; discussion 8–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol. 2009;55(6):1419–27.CrossRefPubMedGoogle Scholar
  26. 26.
    Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer. 2009;115(13):2844–52.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Fernando HS, Duvuru S, Hawkyard SJ. Conservative management of renal masses in the elderly: our experience. Int Urol Nephrol. 2007;39(1):203–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J Urol. 2007;177(2):466–70; discussion 70.CrossRefPubMedGoogle Scholar
  29. 29.
    Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy–natural history, complications, and outcome. Urology. 2004;64(5):909–13.CrossRefPubMedGoogle Scholar
  30. 30.
    Matsuzaki M, Kawano Y, Morikawa H, Shiga Y, Murata H, Komatsu H. Conservative management of small renal tumors. Hinyokika Kiyo. 2007;53(4):207–11.PubMedGoogle Scholar
  31. 31.
    Rosales JC, Haramis G, Moreno J, Badani K, Benson MC, McKiernan J, et al. Active surveillance for renal cortical neoplasms. J Urol. 2010;183(5):1698–702.CrossRefPubMedGoogle Scholar
  32. 32.
    Siu W, Hafez KS, Johnston WK 3rd, Wolf JS Jr. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 2007;25(2):115–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol. 2004;11(5):2407–10.PubMedGoogle Scholar
  34. 34.
    Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738–45.CrossRefPubMedGoogle Scholar
  35. 35.
    Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology. 2004;64(1):49–52.CrossRefPubMedGoogle Scholar
  36. 36.
    Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can Urol Assoc J. 2007;1(2):120–2.PubMedPubMedCentralGoogle Scholar
  37. 37.
    McIntosh AG, Ristau BT, Ruth K, Jennings R, Ross E, Smaldone MC, et al. Active surveillance for localized renal masses: tumor growth, delayed intervention rates, and >5-yr clinical outcomes. Eur Urol. 2018;74(2):157–64.CrossRefPubMedGoogle Scholar
  38. 38.
    Uzosike AC, Patel HD, Alam R, Schwen ZR, Gupta M, Gorin MA, et al. Growth kinetics of small renal masses on active surveillance: variability and results from the DISSRM registry. J Urol. 2017;199(3):641–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Organ M, Jewett M, Basiuk J, Morash C, Pautler S, Siemens DR, et al. Growth kinetics of small renal masses: a prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Can Urol Assoc J. 2014;8(1–2):24–7.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Smaldone MC, Kutikov A, Egleston BL, Canter DJ, Viterbo R, Chen DY, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer. 2012;118(4):997–1006.CrossRefPubMedGoogle Scholar
  41. 41.
    Pierorazio PM, Patel HD, Johnson MH, Sozio SM, Sharma R, Iyoha E, et al. Distinguishing malignant and benign renal masses with composite models and nomograms: a systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy. Cancer. 2016;122(21):3267–76.CrossRefPubMedGoogle Scholar
  42. 42.
    Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425–31.CrossRefPubMedGoogle Scholar
  43. 43.
    Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):20of metastatic event33–6.Google Scholar
  44. 44.
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6 Pt 1):2217–20.CrossRefPubMedGoogle Scholar
  45. 45.
    Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J Urol. 2009;181(1):29–33; discussion 4.CrossRefPubMedGoogle Scholar
  46. 46.
    Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J Urol. 2009;181(3):1020–7. discussion 7.CrossRefPubMedGoogle Scholar
  47. 47.
    Thompson RH, Hill JR, Babayev Y, Cronin A, Kaag M, Kundu S, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol. 2009;182(1):41–5.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kunkle DA, Crispen PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J Urol. 2007;177(5):1692–6; discussion 7.CrossRefPubMedGoogle Scholar
  49. 49.
    Dodelzon K, Mussi TC, Babb JS, Taneja SS, Rosenkrantz AB. Prediction of growth rate of solid renal masses: utility of MR imaging features–preliminary experience. Radiology. 2012;262(3):884–93.CrossRefPubMedGoogle Scholar
  50. 50.
    Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172(1):63–5.CrossRefPubMedGoogle Scholar
  51. 51.
    Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, et al. Prospective evaluation of (99 m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69(3):413–6.CrossRefPubMedGoogle Scholar
  52. 52.
    Uzzo RG. Renal masses–to treat or not to treat? If that is the question are contemporary biomarkers the answer? J Urol. 2008;180(2):433–4.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009;182(6):2585–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol. 2007;178(2):429–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Crispen PL, Blute ML. Do percutaneous renal tumor biopsies at initial presentation affect treatment strategies? Eur Urol. 2009;55(2):307–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC. Renal mass biopsy: always, sometimes, or never? Eur Urol. 2016;70(3):403–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Richard PO, Jewett MA, Bhatt JR, Kachura JR, Evans AJ, Zlotta AR, et al. Renal tumor biopsy for small renal masses: a single-center 13-year experience. Eur Urol. 2015;68(6):1007–13.CrossRefPubMedGoogle Scholar
  58. 58.
    Volpe A, Kachura JR, Geddie WR, Evans AJ, Gharajeh A, Saravanan A, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178(2):379–86.CrossRefPubMedGoogle Scholar
  59. 59.
    Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy–a renaissance? J Urol. 2008;179(1):20–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73(3):586–90; discussion 90–1.CrossRefPubMedGoogle Scholar
  61. 61.
    Neuzillet Y, Lechevallier E, Andre M, Daniel L, Coulange C. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171(5):1802–5.CrossRefPubMedGoogle Scholar
  62. 62.
    Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf JS Jr, Wood DP Jr. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188(2):563–70.CrossRefPubMedGoogle Scholar
  63. 63.
    Lechevallier E, Andre M, Barriol D, Daniel L, Eghazarian C, De Fromont M, et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology. 2000;216(2):506–10.CrossRefPubMedGoogle Scholar
  64. 64.
    Leveridge MJ, Finelli A, Kachura JR, Evans A, Chung H, Shiff DA, et al. Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol. 2011;60(3):578–84.CrossRefPubMedGoogle Scholar
  65. 65.
    Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5; quiz 295.CrossRefPubMedGoogle Scholar
  66. 66.
    Leveridge M, Shiff D, Chung H, Legere L, Fernandes K, Evans A, et al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J Urol. 2010;183(4):e321.Google Scholar
  67. 67.
    Blumenfeld AJ, Guru K, Fuchs GJ, Kim HL. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology. 2010;76(3):610–3.CrossRefPubMedGoogle Scholar
  68. 68.
    Khan AA, Shergill IS, Quereshi S, Arya M, Vandal MT, Gujral SS. Percutaneous needle biopsy for indeterminate renal masses: a national survey of UK consultant urologists. BMC Urol. 2007;7:10.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Wood BJ, Khan MA, McGovern F, Harisinghani M, Hahn PF, Mueller PR. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161(5):1470–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Richard PO, Lavallee LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, et al. Is routine renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses? J Urol. 2018;200(4):731–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Jewett MA, Zuniga A. Renal tumor natural history: the rationale and role for active surveillance. Urol Clin North Am. 2008;35(4):627–34; vii.CrossRefPubMedGoogle Scholar
  72. 72.
    Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology. 2008;72(1):138–42.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Review. Radiology. 1991;178(1):253–8.CrossRefPubMedGoogle Scholar
  74. 74.
    Abe M, Saitoh M. Selective renal tumour biopsy under ultrasonic guidance. Br J Urol. 1992;70(1):7–11.CrossRefPubMedGoogle Scholar
  75. 75.
    Auvert J, Abbou CC, Lavarenne V. Needle tract seeding following puncture of renal oncocytoma. Prog Clin Biol Res. 1982;100:597–8.PubMedGoogle Scholar
  76. 76.
    Gibbons RP, Bush WH Jr, Burnett LL. Needle tract seeding following aspiration of renal cell carcinoma. J Urol. 1977;118(5):865–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Kiser GC, Totonchy M, Barry JM. Needle tract seeding after percutaneous renal adenocarcinoma aspiration. J Urol. 1986;136(6):1292–3.CrossRefPubMedGoogle Scholar
  78. 78.
    Shenoy PD, Lakhkar BN, Ghosh MK, Patil UD. Cutaneous seeding of renal carcinoma by Chiba needle aspiration biopsy. Case report. Acta Radiol. 1991;32(1):50–2.CrossRefPubMedGoogle Scholar
  79. 79.
    Wehle MJ, Grabstald H. Contraindications to needle aspiration of a solid renal mass: tumor dissemination by renal needle aspiration. J Urol. 1986;136(2):446–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Giorgadze T, Qureshi F, Aulicino M, Jacques SM. Retroperitoneal recurrence of a stage 1 renal cell carcinoma four years following core biopsy and fine needle aspiration: possible needle tract seeding. Diagn Cytopathol. 2012;41(5):474.CrossRefPubMedGoogle Scholar
  81. 81.
    Jilani G, Mohamed D, Wadia H, Ramzi K, Meriem J, Houssem L, et al. Cutaneous metastasis of renal cell carcinoma through percutaneous fine needle aspiration biopsy: case report. Dermatol Online J. 2010;16(2):10.PubMedGoogle Scholar
  82. 82.
    Smith AD, Remer EM, Cox KL, Lieber ML, Allen BC, Shah SN, et al. Bosniak category IIF and III cystic renal lesions: outcomes and associations. Radiology. 2012;262(1):152–60.CrossRefPubMedGoogle Scholar
  83. 83.
    Richter F, Kasabian NG, Irwin RJ Jr, Watson RA, Lang EK. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. Urology. 2000;55(3):348–52.CrossRefPubMedGoogle Scholar
  84. 84.
    Truong LD, Todd TD, Dhurandhar B, Ramzy I. Fine-needle aspiration of renal masses in adults: analysis of results and diagnostic problems in 108 cases. Diagn Cytopathol. 1999;20(6):339–49.CrossRefPubMedGoogle Scholar
  85. 85.
    Visapaa H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003;61(4):845–50.CrossRefPubMedGoogle Scholar
  86. 86.
    Delahunt B, Bethwaite PB, Thornton A, Ribas JL. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome. Cancer. 1995;75(11):2714–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Shiina H, Igawa M, Urakami S, Shirakawa H, Ishibe T, Kawanishi M. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma. Eur Urol. 1997;31(1):73–80.CrossRefPubMedGoogle Scholar
  88. 88.
    Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, et al. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005;173(3):725–8.CrossRefPubMedGoogle Scholar
  89. 89.
    Zhang X, Takenaka I. Cell proliferation and apoptosis with BCL-2 expression in renal cell carcinoma. Urology. 2000;56(3):510–5.CrossRefPubMedGoogle Scholar
  90. 90.
    Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35(1):133–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Bilim V, Yuuki K, Itoi T, Muto A, Kato T, Nagaoka A, et al. Double inhibition of XIAP and Bcl-2 axis is beneficial for retrieving sensitivity of renal cell cancer to apoptosis. Br J Cancer. 2008;98(5):941–9.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G. Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer. 1999;84(3):268–72.CrossRefPubMedGoogle Scholar
  93. 93.
    Sabo E, Miselevich I, Bejar J, Segenreich M, Wald M, Moskovitz B, et al. The role of vimentin expression in predicting the long-term outcome of patients with localized renal cell carcinoma. Br J Urol. 1997;80(6):864–8.CrossRefPubMedGoogle Scholar
  94. 94.
    Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180(2):515–9.CrossRefPubMedGoogle Scholar
  95. 95.
    Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9(2):802–11.PubMedGoogle Scholar
  96. 96.
    Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer. 2008;113(3):450–60.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Oda T, Takahashi A, Miyao N, Yanase M, Masumori N, Itoh N, et al. Cell proliferation, apoptosis, angiogenesis and growth rate of incidentally found renal cell carcinoma. Int J Urol. 2003;10(1):13–8.CrossRefPubMedGoogle Scholar
  98. 98.
    Hicks RJ, Ware RE, Lau EW. PET/CT: will it change the way that we use CT in cancer imaging? Cancer Imaging. 2006;6:S52–62.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat Rev. Urol. 2010;7(5):258–66.CrossRefPubMedGoogle Scholar
  100. 100.
    Lawrentschuk N, Poon AM, Foo SS, Putra LG, Murone C, Davis ID, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005;96(4):540–6.CrossRefPubMedGoogle Scholar
  101. 101.
    Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin Nucl Med. 2006;31(12):788–9.CrossRefPubMedGoogle Scholar
  102. 102.
    Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36(3):422–7.CrossRefPubMedGoogle Scholar
  103. 103.
    Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8(4):304–10.CrossRefPubMedGoogle Scholar
  104. 104.
    Uzzo RG, Russo P, Chen D, Larson S, Bahnson R, Libertino JA, et al. The multicenter phase III redect trial: a comparative study of 124 I-girentuximab-PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell Renal Cell Carcinoma (ccRCC) (late breaking abstract; AUA, San Francisco). 2010.Google Scholar
  105. 105.
    Schachter LR, Bach AM, Snyder ME, Kattan MW, Russo P. The impact of tumour location on the histological subtype of renal cortical tumours. BJU Int. 2006;98(1):63–6.CrossRefPubMedGoogle Scholar
  106. 106.
    Venkatesh R, Weld K, Ames CD, Figenshau SR, Sundaram CP, Andriole GL, et al. Laparoscopic partial nephrectomy for renal masses: effect of tumor location. Urology. 2006;67(6):1169–74; discussion 74.CrossRefPubMedGoogle Scholar
  107. 107.
    Weizer AZ, Gilbert SM, Roberts WW, Hollenbeck BK, Wolf JS Jr. Tailoring technique of laparoscopic partial nephrectomy to tumor characteristics. J Urol. 2008;180(4):1273–8.CrossRefPubMedGoogle Scholar
  108. 108.
    Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol. 2011;60(2):241–8.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;163(3):730–6.CrossRefPubMedGoogle Scholar
  110. 110.
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109(9):1763–8.CrossRefPubMedGoogle Scholar
  111. 111.
    Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am. 2008;35(4):613–25; vii.CrossRefPubMedGoogle Scholar
  112. 112.
    Kutikov A, Egleston BL, Smaldone MC, Canter D, Wong YN, Uzzo RG. Quantification of competing risks of death in patients with localized Renal Cell Carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities. J Urol. 2012;188(6):2077–83.Google Scholar
  113. 113.
    Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M. Renal replacement in end-stage renal disease patients over 75 years old. Am J Nephrol. 2003;23(2):71–7.CrossRefPubMedGoogle Scholar
  114. 114.
    Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.CrossRefGoogle Scholar
  115. 115.
    Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007;177(3):849–53; discussion 53–4.CrossRefPubMedGoogle Scholar
  116. 116.
    Crispen PL, Wong YN, Greenberg RE, Chen DY, Uzzo RG. Predicting growth of solid renal masses under active surveillance. Urol Oncol. 2008;26(5):555–9.CrossRefPubMedPubMedCentralGoogle Scholar
  117. 117.
    Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 Pt 1):7067–71.PubMedGoogle Scholar
  118. 118.
    Mues AC, Haramis G, Badani K, Gupta M, Benson MC, McKiernan JM, et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology. 2010;76(3):620–3.CrossRefPubMedGoogle Scholar
  119. 119.
    Neuzillet Y, Lechevallier E, Andre M, Daniel L, Nahon O, Coulange C. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology. 2005;66(6):1181–5.CrossRefPubMedGoogle Scholar
  120. 120.
    Kawaguchi S, Fernandes KA, Finelli A, Robinette M, Fleshner N, Jewett MA. Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance. J Urol. 2011;186(4):1218–22.CrossRefPubMedGoogle Scholar
  121. 121.
    Jewett MA, Finelli A, Morash C, Chin JL, Siemens R, Tanguay S, et al. Active surveillance of small renal masses: a prospective multi-center Canadian Uro-Oncology Group Trial: Abstract No. 896. J Urol. 2009;181(4 supplement):320.CrossRefGoogle Scholar
  122. 122.
    Heilbrun ME, Yu J, Smith KJ, Dechet CB, Zagoria RJ, Roberts MS. The cost-effectiveness of immediate treatment, percutaneous biopsy and active surveillance for the diagnosis of the small solid renal mass: evidence from a Markov model. J Urol. 2012;187(1):39–43.CrossRefPubMedGoogle Scholar
  123. 123.
    Chang SL, Cipriano LE, Harshman LC, Garber AM, Chung BI. Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J Urol. 2011;185(5):1591–7.CrossRefPubMedGoogle Scholar
  124. 124.
    Cooperberg MR, et al. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the national cancer database, 1993 to 2004. J Urol. 2008;179(6):2132.CrossRefGoogle Scholar
  125. 125.
    Ristau BT, et al. Active surveillance for small renal masses: when less is more. Eur Urol Focus. 2016;2(6):660–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Benjamin T. Ristau
    • 1
  • Anthony Corcoran
    • 2
  • Marc C. Smaldone
    • 3
  • Robert G. Uzzo
    • 3
  • David Y. T. Chen
    • 3
    Email author
  1. 1.Department of Surgery/Division of UrologyUConn HealthFarmingtonUSA
  2. 2.Department of UrologyNYU Winthrop HospitalGarden CityUSA
  3. 3.Department of Surgical Oncology, Division of UrologyFox Chase Cancer Center – Temple University Health SystemPhiladelphiaUSA

Personalised recommendations